Emerging Sub-Segments Transforming the Isosorbide Mononitrate Tablet Market Landscape

The market for isosorbide mononitrate tablets is on track for steady expansion over the coming years, driven by various healthcare advancements and growing patient needs. This report delves into the market size, influential companies, prevailing trends, and key segments shaping the future of this cardiovascular medication sector.

Projected Growth Trajectory of the Isosorbide Mononitrate Tablet Market
The isosorbide mononitrate tablet market is anticipated to experience significant growth, reaching a value of $1.55 billion by 2030. This represents a compound annual growth rate (CAGR) of 5.3%. This positive outlook is fueled by an increase in chronic cardiovascular diseases, a rising preference for extended-release tablet formulations, greater use of online pharmacies, better diagnosis rates for conditions like angina and heart failure, and improved availability of cardiovascular treatments in emerging regions. Important trends expected to impact the market include the adoption of long-acting cardiovascular maintenance therapies, a growing inclination toward extended-release products, an increase in generic nitrate usage, enhanced patient compliance through once-daily dosing, and the expansion of accessibility through both online and retail pharmacy channels.

Download a free report of the isosorbide mononitrate tablet market report:
https://www.thebusinessresearchcompany.com/report/isosorbide-mononitrate-tablet-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Prominent Players Leading the Isosorbide Mononitrate Tablet Market
Several major pharmaceutical companies play a vital role in this market, including Pfizer Inc., Merck & Co., Inc., AstraZeneca plc, Abbott Laboratories, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Cipla Ltd., and Zydus Lifesciences Limited. Other key contributors include Torrent Pharmaceuticals Ltd., Micro Labs Ltd., Lupin Limited, Dr. Reddy's Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd., Mylan N.V., Hikma Pharmaceuticals PLC, Sandoz International GmbH, Qilu Pharmaceutical Co., Ltd., Lunan Pharmaceutical Group, and Shandong Keyuan Pharmaceutical Co., Ltd.

Recent Corporate Movement Enhancing Industry Capabilities
In August 2024, BioIVT LLC, a US-based provider specializing in biospecimen solutions, acquired ZenBio Inc., a biotechnology firm focused on human exosome research products. This strategic acquisition, involving an undisclosed sum, strengthens BioIVT's expertise in cell and tissue models and broadens its portfolio of premium biological materials for research and drug development.

View the full isosorbide mononitrate tablet market report:
https://www.thebusinessresearchcompany.com/report/isosorbide-mononitrate-tablet-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Emerging Technological Trends in Patient Transfer Devices
Innovative technological advances are shaping the patient lateral transfer sector, with companies emphasizing lift-free, air-assisted patient positioning devices. These devices improve the safety and ease of patient transfers, reduce physical strain on caregivers, and support a variety of complex clinical positions. By utilizing air channels, friction-reducing surfaces, and optimized pad designs, these products facilitate smooth lateral transfers even for patients with high BMI or limited mobility. For example, in February 2024, Xodus Medical, a medical device firm based in the US, introduced two new versions of its Pink Pad Air-Assist system. The Pink Pad Air-Assist Trendelenburg includes an additional distal air channel to enhance the lifting and transfer of heavier patients. Meanwhile, the Pink Pad Air-Assist EXT + Trendelenburg extends to 72 inches and features upgraded air channels and pad strips, offering versatile and secure patient repositioning across diverse clinical needs.

Key Segments Defining the Isosorbide Mononitrate Tablet Market
This market is segmented based on dosage form, indication type, and distribution channels.
1) Dosage Form: Immediate-Release Tablets and Extended-Release Tablets
2) Indication Type: Angina Pectoris and Coronary Artery Disease (CAD)
3) Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies

Further subcategories include:
- Immediate-Release Tablets: Low-Dose and Single Strength Tablets
- Extended-Release Tablets: Moderate-Dose, High-Dose, Once-Daily Formulations, and Twice-Daily Formulations

These classifications provide detailed insights into product variants and their specific applications within the cardiovascular treatment landscape.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.